Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech fireworks -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (3203)	8/29/2007 12:49:49 PM
From: tuck	Respond to of 7424

Vermillion (VRML), the renamed Ciphergen, is up 18% on this: >>Vermillion, Inc. to Host Teleconference and Webcast on Thursday, August 30, 2007 at 9:00 a.m. Eastern Wednesday August 29, 9:00 am ET FREMONT, Calif., Aug. 29 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML - News), will host a teleconference and webcast on Thursday, August 30 at 9:00 a.m. Eastern Time to discuss its name change and provide an update on business developments. To access the live conference call via phone, dial (877) 325-7371 from the United States and Canada or (706) 634-0768 internationally. The conference ID is 21347583. Please dial-in approximately ten minutes prior to the start of the call. Additionally, you may access the live and subsequently archived webcast of the conference call from the Investor Relations section of the Company's website at vermillion.com. Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary. (Audio: videonewswire.com A telephone replay will be available beginning approximately two hours after the call through Sept 13, 2007 and may be accessed by dialing (800) 633-8284 from the United States and Canada or (+1 402) 977-9140 internationally. The replay passcode is 21347583. An archived replay of the webcast will be available until the next quarterly call. About Vermillion, Inc. Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has ongoing diagnostic programs in oncology/hematology, cardiology and women's health with an initial focus in ovarian cancer. Based in Fremont, California, more information about Vermillion can be found on the Web at vermillion.com.<< This has caused it to vault out of penny stock status again -- barely. Not sure why the enthusiasm, but to borrow a TexasDude phrase, one can hope they will give color on the launch of its ovarian cancer diagnostic test, which is in the hands of Quest. Pretty please, sugar on top? Been waiting a couple of years for such a treat. Cheers, Tuck